Isoguvacine
| Clinical data | |
|---|---|
| Drug class | GABAA receptor agonist |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.150.537 |
| Chemical and physical data | |
| Formula | C6H9NO2 |
| Molar mass | 127.143 g·mol−1 |
| 3D model (JSmol) | |
| |
Isoguvacine is a GABAA receptor agonist used in scientific research.[1] It is a highly charged zwitterion and is unable to enter the central nervous system or produce central mediated effects.[2]
See also
References
- ^ Wahab A, Heinemann U, Albus K (October 2009). "Effects of gamma-aminobutyric acid (GABA) agonists and a GABA uptake inhibitor on pharmacoresistant seizure like events in organotypic hippocampal slice cultures". Epilepsy Research. 86 (2–3): 113–23. doi:10.1016/j.eplepsyres.2009.05.008. PMID 19535226. S2CID 32999271.
- ^ Wafford KA, Ebert B (February 2006). "Gaboxadol--a new awakening in sleep". Curr Opin Pharmacol. 6 (1): 30–36. doi:10.1016/j.coph.2005.10.004. PMID 16368265.
Early studies demonstrated that the highly charged zwitterions isoguvacine and P4S were unable to enter the CNS or exert any pharmacological activity, whereas muscimol and (to an even larger extent) gaboxadol produced observable changes in behaviour after systemic application [25].